FDA Wants More Info From Discovery Laboratories

The Food and Drug Administration requested more information on Discovery Laboratories Inc.'s (DSCO) Surfaxin treatment for premature infant lungs, delaying release of the drug by at least another quarter. Shares of the biotechnology firm tumbled $2.07 to close at $5.02.